Aligos Therapeutics, Inc. (ALGS), a clinical-stage biopharmaceutical company, is dedicated to becoming a world leader in the treatment of viral diseases and liver diseases associated with chronic Hepatitis B (CHB) and other liver disorders. The company, headquartered in South San Francisco, California, aims to develop innovative therapeutics to address global medical needs that have not yet been met.
Aligos’ portfolio underscores their commitment to tackle healthcare challenges that affect millions worldwide. They focus on the development of targeted antiviral therapies for chronic Hepatitis B and coronaviruses as well as therapeutics for nonalcoholic steatohepatitis (NASH). Their multi-pronged approach targets different aspects of viral infections and liver diseases, demonstrating the ambition to bring comprehensive solutions to these complex health issues.
Aligos Therapeutics, Inc. is led by an experienced team of pioneering experts in drug discovery and development, with a proven track record in virology and liver disease. Working together with a shared vision, their collective effort allows them to innovate, push boundaries and advance their quest for novel therapies that treat and prevent viral and liver diseases.
The company's lead drug candidates currently under development include ALG-10xxx series for treating chronic hepatitis B, ALG-000184, a capsid assembly modulator, and a S-antigen transport-inhibiting oligonucleotide polymer. The company's programs are aimed at harnessing timely and innovative strategies that take on the unmet need in viral and liver diseases.
Since its inception in 2018, Aligos Therapeutics has been on a mission to rid the world of viral infections and liver-related diseases. While still a relatively new player, the company has already made significant strides in pursuit of this goal, including the successful initiation of clinical studies for its leading Hepatitis B and NASH drug candidates.
Aligos is committed to its patients, shareholders, and the wider medical community. They operate with a deep sense of responsibility, with each step forward in their research representing a potential leap forward for those affected by viral diseases and liver disorders.
In a world where the burdens and challenges of liver and viral diseases remain high, the importance of companies like Aligos Therapeutics, Inc. cannot be overstated. They are making crucial headway in an ongoing battle against these conditions, bringing hope to millions suffering from these diseases. Through their innovative therapies and comprehensive approach, Aligos Therapeutics is playing a pivotal role in transforming the healthcare landscape.